Join our daily newsletter At The Bell to receive exclusive market insights
- Starpharma’s (SPL) VIRALEZE antiviral nasal spray has been registered for sale in Vietnam
- The VIRALEZE product launch is scheduled to occur in Vietnam this week, with the product supplied under a supply distribution arrangement with Healthco Australia and Vietnam-based Truong Bao Land International Investment Company
- Given the impact of the current COVID outbreak, a portion of VIRALEZE from the initial supply orders will be donated to hospitals and other healthcare organisations in Vietnam
- A further ongoing distribution agreement for additional larger orders of VIRALEZE is being finalised, which will allow subsequent orders and ongoing supply in Vietnam
- Starpharma is up 10.6 per cent, trading at $1.20
Starpharma’s (SPL) VIRALEZE product has been registered for sale in Vietnam.
VIRALEZE is an antiviral nasal spray which provides a physical barrier to trap and inactivate viruses, including SARS-CoV-2.
The product launch is scheduled to occur in Vietnam this week, with the product supplied under a distribution arrangement with Healthco Australia and Vietnam-based Truong Bao Land International Investment Company (TBL).
TBL will use the local medical distribution networks in Vietnam to distribute the product, including Nam Thanh Trade and Medical Services Company.
Vietnam is home to around 98 million and is currently experiencing a significant COVID-19 Delta outbreak, yet has only seen roughly half its population fully vaccinated.
Given the impact of the current outbreak, a portion of VIRALEZE from the initial supply orders will be donated to hospitals and other healthcare organisations in Vietnam.
A further ongoing distribution agreement for additional larger orders of VIRALEZE is being finalised, which will allow subsequent orders and ongoing supply in Vietnam.
“Starpharma is pleased to have achieved another registration for VIRALEZE, and we are excited to see the product launched in Vietnam this week,” CEO Dr Jackie Fairley said.
“This registration, the first in South East Asia, builds upon existing submissions as well as registrations already achieved in Europe, India and New Zealand, and we are expediting further regulatory submissions in multiple regions and countries.”
VIRALEZE is now registered in Europe, Vietnam, India, and New Zealand, plus is available in certain markets online.
Starpharma was up 10.6 per cent, trading at $1.20 at 2:53 pm AEDT.
